Study: Exposing atopic skin to nature-based microbial extract reduces patients’ need for atopy medication
A Health Incubator Helsinki company Uute Scientific has published a pioneering study on a new supportive treatment for atopic dermatitis, based on natural microbial exposure.
The modern lifestyle, characterized by extreme hygiene and limited exposure to nature, has led to a global rise in immune-mediated diseases. The Helsinki-based biotech startup Uute Scientific is fighting against these diseases with its microbial extract, Re-Connecting Nature™. Developed at the University of Helsinki and Tampere University, the extract mimics the biodiversity of Finnish forests, and is already used in approximately 100 beauty and health products.
The company recently released a study showing that exposing atopic skin to nature-based microbial extracts can significantly benefit individuals suffering from atopic dermatitis.
Positive news for atopic patients worldwide
Uute Scientific’s study involved 142 participants diagnosed with atopic dermatitis, split into two groups. One group used a placebo lotion while the other applied a lotion containing the company’s Re-Connecting Nature™ (RCN) extract. Notably, participants using the RCN lotion showed a significant reduction in their need for atopy medication.
Further, the results indicated that the RCN lotion not only reduced medication use but also strengthened the skin’s protective barrier and prevented irritation, especially when autumn turned into winter. This barrier-strengthening effect is significant as skin barrier defect is the key problem in atopic dermatitis.
Uute Scientific’s new study offers hope to over 200 million atopic patients around the world, particularly for those who have experienced unwanted side effects from atopy medications.
“This is truly a historic study that shows scientific evidence of the power of our nature’s microbes to help with severe disease. We start with atopic skin, but other immune-mediated diseases, such as different allergies, asthma, Parkinson’s disease, or Alzheimer’s, are also likely to benefit from this,” says Kari Sinivuori, CEO and co-founder of Uute Scientific.
Photos: Uute Scientific
In the first picture from left to right: Iida Mäkelä, Olli Laitinen, Johanna Kalmari and Saija Snygg
In the second picture: Kari Sinivuori, CEO and co-founder at Uute Scientific
